What documents related to CSCI’s shareholder meeting are attached to the filing?

The filing attaches two key documents: Exhibit 99.1, the Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular dated May 18, 2026, and Exhibit 99.2, the Form of Proxy. These materials give shareholders details and tools to participate and vote.

COSCIENS Biopharma sets June 17 special meeting

COSCIENS Biopharma Inc. filed a Form 6-K as a foreign private issuer to report that its board of directors has called a Special Meeting of Shareholders and Management Proxy Circular.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

COSCIENS Biopharma Inc. filed a Form 6-K as a foreign private issuer to report that its board of directors has called a Special Meeting of Shareholders and Management Proxy Circular.

The meeting is scheduled for June 17, 2026 at 9:30 a.m. Eastern time. Shareholders were sent a notice of the Circular and a form of proxy on or before May 21, 2026. The filing includes as exhibits the Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular, dated May 18, 2026 (Exhibit 99.1), and the Form of Proxy (Exhibit 99.2).

Key Figures

Special Meeting date: June 17, 2026 Meeting time: 9:30 a.m. Eastern time Proxy materials mailing deadline: On or before May 21, 2026 +3 more

6 metrics

Special Meeting date June 17, 2026 Scheduled date for Special Meeting of Shareholders

Meeting time 9:30 a.m. Eastern time Scheduled time for Special Meeting of Shareholders

Proxy materials mailing deadline On or before May 21, 2026 Date by which notice and form of proxy were sent to shareholders

Management Proxy Circular date May 18, 2026 Date of Notice of Annual and Special Meeting and Management Proxy Circular (Exhibit 99.1)

Exhibit 99.1 Notice and Management Proxy Circular Proxy disclosure document for shareholder meeting

Exhibit 99.2 Form of Proxy Voting form for shareholders for the Special Meeting

Key Terms

Form 6-K, foreign private issuer, Special Meeting of Shareholders, Management Proxy Circular, +1 more

5 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Special Meeting of Shareholders financial

"passed a resolution to convene a Special Meeting of Shareholders"

Management Proxy Circular financial

"Special Meeting of Shareholders and Management Proxy Circular (the “Circular”)"

A management proxy circular is a detailed briefing packet mailed or posted to shareholders before a company meeting that asks them to vote on key matters. It lays out agenda items, background information, management’s recommendations, pay and board candidate details, and instructions for authorizing someone to vote on your behalf. Investors use it like an agenda plus briefing notes to decide how votes could affect who controls the company, its strategy and future returns.

Form of Proxy financial

"were sent a notice of the Circular and a form of proxy"

A form of proxy is the official document shareholders use to give someone else instructions or authority to vote their shares at a company meeting when they cannot or choose not to attend. Like filling out a ballot and designating a trusted friend to cast it for you, it lets investors influence board elections, mergers, executive pay and other key decisions without being physically present, so timely review can affect control and value of your investment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did COSCIENS Biopharma (CSCI) disclose in this Form 6-K?

COSCIENS Biopharma disclosed that its board has called a Special Meeting of Shareholders with an accompanying Management Proxy Circular. The Form 6-K also indicates that shareholders received a notice and form of proxy and that these documents are filed as Exhibits 99.1 and 99.2.

When is the COSCIENS Biopharma (CSCI) Special Meeting of Shareholders scheduled?

The Special Meeting of Shareholders is scheduled for June 17, 2026 at 9:30 a.m. Eastern time. This timing is specified in the company’s notice and proxy circular, which are attached as Exhibit 99.1 to the Form 6-K filed as a foreign private issuer.

When did COSCIENS Biopharma (CSCI) send proxy materials to shareholders?

Shareholders were sent a notice of the Management Proxy Circular and a form of proxy on or before May 21, 2026. This mailing date ensures investors have time to review proposals and submit voting instructions ahead of the June 17, 2026 Special Meeting of Shareholders.

What is the purpose of the Management Proxy Circular for COSCIENS Biopharma (CSCI)?

The Management Proxy Circular provides information to shareholders about matters to be considered at the Special Meeting of Shareholders. It accompanies the notice and Form of Proxy, enabling shareholders to make informed voting decisions in connection with the meeting scheduled for June 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/20/2026 - 04:38 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2026

Commission File Number: 001-38064

COSCIENS Biopharma Inc.

(Translation of registrant’s name into English)

c/o Borden Ladner Gervais, LLP

22 Adelaide St. West, Suite 3400

Bay Adelaide Centre, East Tower

Toronto ON M5H 4E3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

The board of directors of COSCIENS Biopharma Inc. (the “Company”) passed a resolution to convene a Special Meeting of Shareholders and Management Proxy Circular (the “Circular”) of the Company on June 17, 2026 at 9:30 am (Eastern time).

On or before May 21, 2026, the shareholders of the Company were sent a notice of the Circular and a form of proxy.

DOCUMENTS INDEX

Exhibit		Description
99.1		Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular, dated May 18, 2026.
99.2		Form of Proxy.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.